Literature DB >> 2969798

Effects of different antihypertensive drugs on left ventricular function.

R Oliveri1.   

Abstract

Left ventricular hypertrophy (LVH) is a response by the heart to haemodynamic overload. It is frequently observed in hypertension as a consequence of work overload secondary to an increased systemic resistance. This increase is not the only cause of LVH; there are other factors which can have a significant effect on its incidence. LVH in arterial hypertension acts initially as a useful compensatory mechanism against increased peripheral resistance. However after a certain amount of time it produces changes of variable intensity which have important consequences for the heart and some of them impair cardiac performance: 1. It affects both systolic and diastolic ventricular function; 2. It reduces coronary reserve; 3. It increases the incidence of angina and heart failure; 4. It increases the incidence of ventricular arrhythmias and sudden death. It therefore seems reasonable to include the reduction of LVH among the basic aims of antihypertensive treatment. Antisympathetic drugs (methyldopa, prazosin, urapidil), adrenergic beta-blockers, calcium antagonists and the converting enzyme inhibitors have proven to have a variable degree of efficacy in effecting a regression of LVH.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969798     DOI: 10.2165/00003495-198800356-00012

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  38 in total

1.  Cardiac hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; P A Khairallah; F M Bumpus
Journal:  Circ Res       Date:  1974-11       Impact factor: 17.367

2.  Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study.

Authors:  W B Kannel; T Gordon; D Offutt
Journal:  Ann Intern Med       Date:  1969-07       Impact factor: 25.391

3.  Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; T Gordon; W P Castelli; J R Margolis
Journal:  Ann Intern Med       Date:  1970-06       Impact factor: 25.391

4.  The myocardium in hyperfunction, hypertrophy and heart failure.

Authors:  F Z Meerson
Journal:  Circ Res       Date:  1969-07       Impact factor: 17.367

5.  Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack of association with blood pressure control.

Authors:  F M Fouad; Y Nakashima; R C Tarazi; E E Salcedo
Journal:  Am J Cardiol       Date:  1982-03       Impact factor: 2.778

6.  Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy.

Authors:  F H Messerli; H O Ventura; D J Elizardi; F G Dunn; E D Frohlich
Journal:  Am J Med       Date:  1984-07       Impact factor: 4.965

7.  Effect of converting enzyme inhibitor (SQ14,225) on myocardial hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; F M Bumpus
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

8.  Cardiac hypertrophy: useful adaptation or pathologic process?

Authors:  W Grossman
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  Cardiac hypertrophy and antihypertensive therapy.

Authors:  S Sen; R C Tarazi; F M Bumpus
Journal:  Cardiovasc Res       Date:  1977-09       Impact factor: 10.787

10.  The effect of cardiac hypertrophy on the coronary collateral circulation.

Authors:  D G Harrison; D H Barnes; L F Hiratzka; C L Eastham; R E Kerber; M L Marcus
Journal:  Circulation       Date:  1985-06       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.